317 related articles for article (PubMed ID: 17269700)
21. Isolation, solubilization, refolding, and chromatographic purification of human growth hormone from inclusion bodies of Escherichia coli cells: a case study.
Singh SM; Eshwari AN; Garg LC; Panda AK
Methods Mol Biol; 2005; 308():163-76. PubMed ID: 16082034
[No Abstract] [Full Text] [Related]
22. Factors affecting protein refolding yields in a fed-batch and batch-refolding system.
Mannall GJ; Titchener-Hooker NJ; Dalby PA
Biotechnol Bioeng; 2007 Aug; 97(6):1523-34. PubMed ID: 17304557
[TBL] [Abstract][Full Text] [Related]
23. Kinetics of inclusion body formation studied in intact cells by FT-IR spectroscopy.
Ami D; Natalello A; Gatti-Lafranconi P; Lotti M; Doglia SM
FEBS Lett; 2005 Jun; 579(16):3433-6. PubMed ID: 15949804
[TBL] [Abstract][Full Text] [Related]
24. Efficient refolding of the bifunctional therapeutic fusion protein VAS-TRAIL by a triple agent solution.
Fan J; Wang Z; Huang L; Shen Y
Protein Expr Purif; 2016 Sep; 125():68-73. PubMed ID: 26358405
[TBL] [Abstract][Full Text] [Related]
25. Chromatographic methods for the isolation of, and refolding of proteins from, Escherichia coli inclusion bodies.
Gu Z; Weidenhaupt M; Ivanova N; Pavlov M; Xu B; Su ZG; Janson JC
Protein Expr Purif; 2002 Jun; 25(1):174-9. PubMed ID: 12071713
[TBL] [Abstract][Full Text] [Related]
26. Investigation of inclusion body formation in recombinant Escherichia coli with a bioimaging system.
Li RY; Cheng CY
J Biosci Bioeng; 2009 May; 107(5):512-5. PubMed ID: 19393549
[TBL] [Abstract][Full Text] [Related]
27. [Optimization of induction and purification of HIV-1 Gag protein in Escherichia coli expression system].
Fu J; Sun J; Chen P; Huo Z; Hao Y; Liu Y
Sheng Wu Gong Cheng Xue Bao; 2008 Jul; 24(7):1306-11. PubMed ID: 18837413
[TBL] [Abstract][Full Text] [Related]
28. Optimized production of active alpha-glucosidase by recombinant Escherichia coli. evaluation of processes using in vivo reactivation from inclusion bodies.
Le Thanh H; Hoffmann F
Biotechnol Prog; 2005; 21(4):1053-61. PubMed ID: 16080683
[TBL] [Abstract][Full Text] [Related]
29. Renaturation, purification and characterization of streptokinase expressed as inclusion body in recombinant E. coli.
Cherish Babu PV; Srinivas VK; Krishna Mohan V; Krishna E
J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Jan; 861(2):218-26. PubMed ID: 17981102
[TBL] [Abstract][Full Text] [Related]
30. Biological and physicochemical evaluation of the conformational stability of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
Youn YS; Shin MJ; Chae SY; Jin CH; Kim TH; Lee KC
Biotechnol Lett; 2007 May; 29(5):713-21. PubMed ID: 17318333
[TBL] [Abstract][Full Text] [Related]
31. Use of the design-of-experiments approach for the development of a refolding technology for progenipoietin-1, a recombinant human cytokine fusion protein from Escherichia coli inclusion bodies.
Boyle DM; Buckley JJ; Johnson GV; Rathore A; Gustafson ME
Biotechnol Appl Biochem; 2009 Jul; 54(2):85-92. PubMed ID: 19435462
[TBL] [Abstract][Full Text] [Related]
32. Refolding of therapeutic proteins produced in Escherichia coli as inclusion bodies.
Misawa S; Kumagai I
Biopolymers; 1999; 51(4):297-307. PubMed ID: 10618597
[TBL] [Abstract][Full Text] [Related]
33. A single step method for the solubilization and refolding of recombinant protein from E. coli inclusion bodies.
Crivelli E; Cardamone M; Puri NK
Aust J Biotechnol; 1991 Apr; 5(2):78-80, 86. PubMed ID: 1367324
[TBL] [Abstract][Full Text] [Related]
34. A comparative investigation on different refolding strategies of recombinant human tissue-type plasminogen activator derivative.
Liu H; Zhou X; Zhang Y
Biotechnol Lett; 2006 Apr; 28(7):457-63. PubMed ID: 16614926
[TBL] [Abstract][Full Text] [Related]
35. A simplified bioprocess for human alpha-fetoprotein production from inclusion bodies.
Leong SS; Middelberg AP
Biotechnol Bioeng; 2007 May; 97(1):99-117. PubMed ID: 17115449
[TBL] [Abstract][Full Text] [Related]
36. High recovery refolding of rhG-CSF from Escherichia coli, using urea gradient size exclusion chromatography.
Wang C; Wang L; Geng X
Biotechnol Prog; 2008; 24(1):209-13. PubMed ID: 18179225
[TBL] [Abstract][Full Text] [Related]
37. Anti-aggregatory effect of cyclodextrins in the refolding process of recombinant growth hormones from Escherichia coli inclusion bodies.
Bajorunaite E; Cirkovas A; Radzevicius K; Larsen KL; Sereikaite J; Bumelis VA
Int J Biol Macromol; 2009 Jun; 44(5):428-34. PubMed ID: 19428477
[TBL] [Abstract][Full Text] [Related]
38. The cataract-causing mutation G98R in human alphaA-crystallin leads to folding defects and loss of chaperone activity.
Singh D; Raman B; Ramakrishna T; Rao ChM
Mol Vis; 2006 Nov; 12():1372-9. PubMed ID: 17149363
[TBL] [Abstract][Full Text] [Related]
39. Strategy for linker selection to enhance refolding and bioactivity of VAS-TRAIL fusion protein based on inclusion body conformation and activity.
Fan J; Huang L; Sun J; Qiu Y; Zhou J; Shen Y
J Biotechnol; 2015 Sep; 209():16-22. PubMed ID: 26072465
[TBL] [Abstract][Full Text] [Related]
40. Refolding, purification, and activation of miniplasminogen and microplasminogen isolated from E. coli inclusion bodies.
Medynski D; Tuan M; Liu W; Wu S; Lin X
Protein Expr Purif; 2007 Apr; 52(2):395-402. PubMed ID: 17126563
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
